摘要
在骨骼重塑过程中,成骨细胞和破骨细胞相互偶联是维持骨骼正常的关键,而这两种细胞的偶联依赖于骨保护素(osteoprotegerin,OPG)-核因子κB受体活化因子配体(receptor activator of nuclear factor-kappa B ligand,RANKL)-核因子κB受体活化因子(receptor activator of nuclear factor kappa B,RANK)信号通路,该信号通路被发现后,出现了第一个抗骨质疏松分子靶向药物地舒单抗(Denosumab,2018年前曾称之为迪诺塞麦)。该药物的出现,代表抗骨质疏松治疗进入了一个新的时代,即分子靶向治疗时代。本文重点介绍OPG-RANKL-RANK信号通路的发现和地舒单抗的研发历程,并对以地舒单抗和随后出现的罗莫珠单抗(Romosozumab)为代表的分子靶向药物的临床研究结果进行阐述。
During the remodeling of the bone,the coupling between osteoblasts and osteoclasts is the key to maintain normal bone,which depends on the osteoprotegerin(OPG)-receptor activator of nuclear factor-kappa B ligand(RANKL)-receptor activator of nuclear factor-kappa B(RANK)signaling pathway.After the discovery of this pathway,the first molecular targeted drug Denosumab for treating osteoporosis appeared,the emergence of this drug represents that the anti-osteoporosis treatment has entered a new era,which is the era of molecular targeted therapy.This paper focuses on the discovery of OPG-RANKL-RANK signaling pathway and the development process of Denosumab,and the clinical research results of molecular targeted drugs represented by Denosumab and Romosozumab appeared subsequently are reviewed.
作者
谢忠建
XIE Zhong-jian(National Clinical Research Center for Metabolic Diseases,Institute of Metabolism and Endocrinology,and Department of Metabolism and Endocrinology,The Second Xiangya Hospital of Central South University,Changsha 410011,China)
出处
《中华骨质疏松和骨矿盐疾病杂志》
CSCD
北大核心
2022年第2期126-134,共9页
Chinese Journal Of Osteoporosis And Bone Mineral Research
基金
国家重点研发计划(2021YFC2501700)
国家自然科学基金(81471055,81672646,82171580)
湖南省自然科学基金(2021JJ30035)。
